Matsubara, Japan

Tetsuya Hosono

This inventor holds 1 USPTO granted patent, plus 1 CIPO patent and 1 EPO patent. Top assignee: Fujimoto Co., Ltd.. Active years: 2013.




Average Co-Inventor Count = 4.0

ph-index = 1


Company Filing History:


Years Active: 2013

Loading Chart...
Loading Chart...
Loading Chart...
1 patent (USPTO):Explore Patents

Title: Tetsuya Hosono: Innovator in Sustained Release Micropellets

Introduction

Tetsuya Hosono is a notable inventor based in Matsubara, Japan. He has made significant contributions to the field of medicinal compositions through his innovative work on sustained release micropellets. His inventions focus on improving drug delivery systems, which are crucial for effective medical treatments.

Latest Patents

Tetsuya Hosono holds a patent for "Sustained release micropellets and process for producing the same." This invention describes a method for creating micropellets that provide a stable controlled release of a drug, unaffected by changes in pH levels. The process involves coating core particles with a layer containing a water-soluble drug, followed by a film layer made of a water-insoluble polymer compound and a plasticizer. Additionally, a water-soluble filler layer is placed between the drug-containing layer and the film layer, resulting in micropellets with an average particle size of 300 µm or less.

Career Highlights

Tetsuya Hosono is associated with Fujimoto Co., Ltd., where he continues to develop innovative solutions in the pharmaceutical field. His work has been instrumental in advancing drug delivery technologies, making medications more effective and reliable for patients.

Collaborations

Tetsuya has collaborated with notable colleagues such as Fumiya Hamano and Fumio Yoneda. Their combined expertise has contributed to the success of various projects within the company.

Conclusion

Tetsuya Hosono's contributions to the field of sustained release micropellets highlight his innovative spirit and dedication to improving drug delivery systems. His work continues to impact the pharmaceutical industry positively.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to [email protected]
Loading…